CN104066447A - 重组蛋白及其治疗用途 - Google Patents

重组蛋白及其治疗用途 Download PDF

Info

Publication number
CN104066447A
CN104066447A CN201280067891.1A CN201280067891A CN104066447A CN 104066447 A CN104066447 A CN 104066447A CN 201280067891 A CN201280067891 A CN 201280067891A CN 104066447 A CN104066447 A CN 104066447A
Authority
CN
China
Prior art keywords
somatomedin
recombiant
proteins
protein
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280067891.1A
Other languages
English (en)
Chinese (zh)
Inventor
基思·艾伦·查尔顿
E·德杭特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
In3bio Ltd
Original Assignee
Bioven 3 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioven 3 Ltd filed Critical Bioven 3 Ltd
Priority to CN201810569766.XA priority Critical patent/CN108864291A/zh
Priority to CN201810569310.3A priority patent/CN108864261A/zh
Publication of CN104066447A publication Critical patent/CN104066447A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/28—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201280067891.1A 2011-11-23 2012-11-21 重组蛋白及其治疗用途 Pending CN104066447A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201810569766.XA CN108864291A (zh) 2011-11-23 2012-11-21 重组蛋白及其治疗用途
CN201810569310.3A CN108864261A (zh) 2011-11-23 2012-11-21 重组蛋白及其治疗用途

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161563128P 2011-11-23 2011-11-23
US61/563,128 2011-11-23
US201261654401P 2012-06-01 2012-06-01
US61/654,401 2012-06-01
PCT/IB2012/002876 WO2013076580A2 (en) 2011-11-23 2012-11-21 Recombinant proteins and their therapeutic uses

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN201810569310.3A Division CN108864261A (zh) 2011-11-23 2012-11-21 重组蛋白及其治疗用途
CN201810569766.XA Division CN108864291A (zh) 2011-11-23 2012-11-21 重组蛋白及其治疗用途

Publications (1)

Publication Number Publication Date
CN104066447A true CN104066447A (zh) 2014-09-24

Family

ID=47716105

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201280067891.1A Pending CN104066447A (zh) 2011-11-23 2012-11-21 重组蛋白及其治疗用途
CN201810569766.XA Pending CN108864291A (zh) 2011-11-23 2012-11-21 重组蛋白及其治疗用途
CN201810569310.3A Pending CN108864261A (zh) 2011-11-23 2012-11-21 重组蛋白及其治疗用途

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201810569766.XA Pending CN108864291A (zh) 2011-11-23 2012-11-21 重组蛋白及其治疗用途
CN201810569310.3A Pending CN108864261A (zh) 2011-11-23 2012-11-21 重组蛋白及其治疗用途

Country Status (22)

Country Link
US (5) US9902760B2 (enExample)
EP (2) EP3744343A1 (enExample)
JP (4) JP6121436B2 (enExample)
KR (2) KR102274211B1 (enExample)
CN (3) CN104066447A (enExample)
AU (3) AU2012342117B2 (enExample)
BR (1) BR112014012460B1 (enExample)
CA (1) CA2856255C (enExample)
DK (1) DK2782598T3 (enExample)
ES (1) ES2812564T3 (enExample)
HR (1) HRP20201282T1 (enExample)
HU (1) HUE050438T2 (enExample)
IL (2) IL232645B (enExample)
LT (1) LT2782598T (enExample)
MX (2) MX354902B (enExample)
MY (2) MY188083A (enExample)
PL (1) PL2782598T3 (enExample)
PT (1) PT2782598T (enExample)
RS (1) RS60782B1 (enExample)
RU (2) RU2650574C2 (enExample)
SI (1) SI2782598T1 (enExample)
WO (1) WO2013076580A2 (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107880133A (zh) * 2017-11-04 2018-04-06 海南大学 促皮质素与胰岛素样生长因子1融合蛋白及其制备方法
CN107949401A (zh) * 2015-05-12 2018-04-20 拜奥文斯瑞有限公司 联合施用酪氨酸激酶抑制剂来抑制表皮生长因子/表皮生长因子受体途径的方法及组合物
WO2019179361A1 (zh) * 2018-03-21 2019-09-26 傅惠芳 改善括约肌闭锁不全的组合物及其医药组成物与用途
CN111246878A (zh) * 2017-07-18 2020-06-05 因斯瑞拜奥有限公司 合成蛋白及其治疗用途
CN112552412A (zh) * 2019-12-05 2021-03-26 屈向东 一种包含TGF-β抑制剂、VEGF抑制剂和抗PDL1抗体的三功能融合蛋白
CN113735980A (zh) * 2021-08-23 2021-12-03 中国医学科学院北京协和医院 一种自融合串联蛋白修饰方法及其应用
CN114269792A (zh) * 2019-06-25 2022-04-01 因斯瑞拜奥有限公司 稳定的嵌合合成蛋白及其治疗用途

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013076580A2 (en) 2011-11-23 2013-05-30 Bioven 3 Limited Recombinant proteins and their therapeutic uses
US20190358320A1 (en) * 2015-05-12 2019-11-28 In3Bio Ltd. Methods and compositions for inhibition of egf/egfr pathway in combination with tyrosine kinase inhibitors
WO2020046982A1 (en) * 2018-08-27 2020-03-05 University Of Virginia Patent Foundation Compositions and methods for preventing and treating virus infection
KR20220099990A (ko) 2019-11-07 2022-07-14 인3바이오 리미티드 비티로신 표적화 키나아제 억제제와 병용하여 성장 인자 항체를 사용하기 위한 방법 및 조성물
US20230097992A1 (en) * 2020-03-25 2023-03-30 The Regents Of The University Of Colorado, A Body Corporate Bivalent egf fusion toxins

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1142973A (zh) * 1993-12-09 1997-02-19 分子免疫中心 具有抗肿瘤活性的疫苗组合物及其在恶性疾病治疗方面的应用
CN101595219A (zh) * 2006-11-13 2009-12-02 阿特纳赞塔里斯有限公司 作为编码抗原和蛋白毒素的核苷酸序列的载体的微生物，其制备方法和用途

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3238190A (en) 1963-10-23 1966-03-01 Madaus & Co K G Fa Dr Aescin recovery
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
CA2261433A1 (en) * 1993-12-09 1995-06-10 Belinda Sanchez Ramirez Composition comprising autologous epidermal growth factor
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
JPH10147952A (ja) 1996-11-18 1998-06-02 Komatsu Ltd ブルドーザのドージング装置
AU734180B2 (en) 1997-08-29 2001-06-07 Antigenics Llc Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as excipient
WO1999025379A1 (en) * 1997-11-14 1999-05-27 Euro-Celtique, S.A. Modified antibodies with enhanced ability to elicit an anti-idiotype response
US6492325B1 (en) * 1998-05-22 2002-12-10 Boys Town National Research Hospital Use of α1β1 integrin receptor inhibitors and TGF-β1 inhibitors in the treatment of kidney disease
DK1187629T3 (da) 1999-04-19 2005-01-17 Glaxosmithkline Biolog Sa Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
US7078486B2 (en) * 1999-12-10 2006-07-18 Spectral Diagnostics, Inc. Single-chain polypeptides comprising troponin I and troponin C
WO2001070985A2 (en) * 2000-03-23 2001-09-27 Greenville Hospital System Bi-functional cancer treatment agents
CU22999A1 (es) 2001-12-04 2004-10-12 Centro Inmunologia Molecular Método de tratamiento de enfermedades malignas e infecciosas crónicas
EP1390065A2 (en) * 2001-05-14 2004-02-25 Duotol Ab Methods for promoting antigen presentation and modulating immune responses using cholera toxin and its b subunit
KR100945108B1 (ko) * 2001-06-13 2010-03-02 젠맵 에이/에스 표피 성장 인자 수용체 (ｅｇｆｒ)에 대한 인간모노클로날 항체
US6833441B2 (en) * 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
JP2004538331A (ja) 2001-08-17 2004-12-24 ロジャー ウィリアムス ホスピタル インサイチュ免疫法
US7332585B2 (en) * 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
KR20050042082A (ko) * 2002-05-31 2005-05-04 시젠 피티와이 리미티드 막 투과 서열로부터 유도된 자가 융합 또는 자가 응집단백질
AU2003900481A0 (en) * 2003-02-05 2003-02-20 Queensland University Of Technology Synthetic modulators of cell migration and growth
US8207314B2 (en) * 2003-05-16 2012-06-26 Sanofi Pasteur Limited Tumor antigens for prevention and/or treatment of cancer
US7601341B2 (en) * 2003-06-05 2009-10-13 Research Development Foundation Vascular endothelial growth factor fusion constructs used to inhibit osteoclastogenesis
JP4623625B2 (ja) 2003-07-24 2011-02-02 株式会社AMBiS ヘテロ型５量体組換えワクチン
US7320795B2 (en) * 2003-07-30 2008-01-22 Vaccine Research Institute Of San Diego Rodent hepatitis B virus core proteins as vaccine platforms and methods of use thereof
EP2634252B1 (en) * 2005-02-11 2018-12-19 University of Southern California Method of expressing proteins with disulfide bridges
FR2882654B1 (fr) * 2005-03-01 2007-04-27 Servier Lab Utilisation de derives de la diosmetine pour le traitement et la prevention des pathologies thrombotiques
CN1686562A (zh) * 2005-03-31 2005-10-26 南京大学 一种转铁蛋白与生物还原剂的结合物及其制备方法
MX2008009970A (es) * 2006-02-01 2008-11-19 Univ Johns Hopkins Conjugados de polipeptido-acido nucleico para inmunoprofilaxis o inmunoterapia para desordenes neoplasicos o infecciosos.
ES2348312T3 (es) * 2006-04-13 2010-12-02 Bio Life Science Forschungs- Und Entwicklungsges.M.B.H. Vacuna her-2/neu a base de múltiples péptidos.
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
WO2008005992A2 (en) 2006-07-06 2008-01-10 Molecular Logix, Inc. Dominant negative ligand drug discovery system
CA2661634C (en) * 2006-09-06 2017-03-28 The Regents Of The University Of California Selectively targeted antimicrobial peptides and the use thereof
CN1995064A (zh) * 2006-12-20 2007-07-11 李欣越 增强生物活性的长效重组人红细胞生长因子融合蛋白及方法
US8057798B2 (en) * 2007-02-02 2011-11-15 Baylor Research Institute Vaccines based on targeting antigen to DCIR expressed on antigen-presenting cells
EP2684889A3 (en) * 2007-02-02 2014-03-05 Baylor Research Institute Multivariable antigens complexed with targeting humanized monoclonal antibody
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
KR101224468B1 (ko) 2009-05-20 2013-01-23 주식회사 파멥신 신규한 형태의 이중표적항체 및 그 용도
JP2011187653A (ja) 2010-03-08 2011-09-22 Olympus Corp 防水機器
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
WO2013076580A2 (en) * 2011-11-23 2013-05-30 Bioven 3 Limited Recombinant proteins and their therapeutic uses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1142973A (zh) * 1993-12-09 1997-02-19 分子免疫中心 具有抗肿瘤活性的疫苗组合物及其在恶性疾病治疗方面的应用
CN101595219A (zh) * 2006-11-13 2009-12-02 阿特纳赞塔里斯有限公司 作为编码抗原和蛋白毒素的核苷酸序列的载体的微生物，其制备方法和用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MICHAEL LEBENS ET AL: "a mucosally administered recombinant fusion protein vaccine against schistosomiasis protecting against immunopathology and infection", 《VACCINE》 *
居乃琥: "《酶工程手册》", 31 August 2011 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107949401A (zh) * 2015-05-12 2018-04-20 拜奥文斯瑞有限公司 联合施用酪氨酸激酶抑制剂来抑制表皮生长因子/表皮生长因子受体途径的方法及组合物
US12258389B2 (en) 2015-05-12 2025-03-25 In3Bio Ltd. Methods and compositions for inhibition of EGF/EGFR pathway in combination with tyrosine kinase inhibitors
US12595297B2 (en) 2015-05-12 2026-04-07 In3Bio Ltd. Methods and compositions for inhibition of EGF/EGFR pathway in combination with tyrosine kinase inhibitors
CN111246878A (zh) * 2017-07-18 2020-06-05 因斯瑞拜奥有限公司 合成蛋白及其治疗用途
US12134662B2 (en) 2017-07-18 2024-11-05 In3Bio Ltd. Synthetic proteins and therapeutic uses thereof
CN107880133A (zh) * 2017-11-04 2018-04-06 海南大学 促皮质素与胰岛素样生长因子1融合蛋白及其制备方法
WO2019179361A1 (zh) * 2018-03-21 2019-09-26 傅惠芳 改善括约肌闭锁不全的组合物及其医药组成物与用途
CN114269792A (zh) * 2019-06-25 2022-04-01 因斯瑞拜奥有限公司 稳定的嵌合合成蛋白及其治疗用途
CN114269792B (zh) * 2019-06-25 2025-08-08 因斯瑞拜奥有限公司 稳定的嵌合合成蛋白及其治疗用途
CN112552412A (zh) * 2019-12-05 2021-03-26 屈向东 一种包含TGF-β抑制剂、VEGF抑制剂和抗PDL1抗体的三功能融合蛋白
CN112552412B (zh) * 2019-12-05 2023-08-18 启愈生物技术(上海)有限公司 一种包含TGF-β抑制剂、VEGF抑制剂和抗PDL1抗体的三功能融合蛋白
CN113735980A (zh) * 2021-08-23 2021-12-03 中国医学科学院北京协和医院 一种自融合串联蛋白修饰方法及其应用

Also Published As

Publication number Publication date
AU2012342117B2 (en) 2017-08-31
KR102024066B1 (ko) 2019-09-24
MX354902B (es) 2018-03-23
IL232645A0 (en) 2014-06-30
RU2650574C2 (ru) 2018-04-17
MY184576A (en) 2021-04-06
HRP20201282T1 (hr) 2020-11-13
US9902760B2 (en) 2018-02-27
RU2018108421A (ru) 2019-02-25
IL232645B (en) 2021-01-31
DK2782598T3 (da) 2020-08-10
US12030920B2 (en) 2024-07-09
CA2856255C (en) 2021-06-22
HUE050438T2 (hu) 2020-12-28
KR20140108235A (ko) 2014-09-05
KR102274211B1 (ko) 2021-07-09
JP7470669B2 (ja) 2024-04-18
US20180162917A1 (en) 2018-06-14
RS60782B1 (sr) 2020-10-30
JP2014534258A (ja) 2014-12-18
AU2012342117A1 (en) 2013-05-30
MX2014006232A (es) 2015-02-10
JP2022023081A (ja) 2022-02-07
SI2782598T1 (sl) 2020-12-31
IL279676A (en) 2021-03-01
JP6953467B2 (ja) 2021-10-27
LT2782598T (lt) 2020-07-27
EP2782598A2 (en) 2014-10-01
US20140248302A1 (en) 2014-09-04
JP2019146576A (ja) 2019-09-05
BR112014012460B1 (pt) 2021-01-12
RU2766595C2 (ru) 2022-03-15
PL2782598T3 (pl) 2021-03-08
CN108864261A (zh) 2018-11-23
JP2017137339A (ja) 2017-08-10
PT2782598T (pt) 2020-09-02
BR112014012460A2 (pt) 2017-06-06
MX381185B (es) 2025-03-12
WO2013076580A3 (en) 2013-08-22
EP2782598B1 (en) 2020-05-27
ES2812564T3 (es) 2021-03-17
AU2020201297A1 (en) 2020-03-12
US20160207972A1 (en) 2016-07-21
AU2012342117A8 (en) 2014-07-03
EP3744343A1 (en) 2020-12-02
AU2017268634B2 (en) 2019-11-21
MY188083A (en) 2021-11-16
WO2013076580A2 (en) 2013-05-30
AU2017268634A1 (en) 2017-12-21
RU2018108421A3 (enExample) 2021-06-04
US11198716B2 (en) 2021-12-14
CA2856255A1 (en) 2013-05-30
CN108864291A (zh) 2018-11-23
JP6570081B2 (ja) 2019-09-04
AU2020201297B2 (en) 2022-03-10
JP6121436B2 (ja) 2017-04-26
KR20190112161A (ko) 2019-10-02
US20220153798A1 (en) 2022-05-19
RU2014124923A (ru) 2015-12-27
US12570708B2 (en) 2026-03-10
US20250066439A1 (en) 2025-02-27

Similar Documents

Publication Publication Date Title
US12570708B2 (en) Recombinant proteins and their therapeutic uses
US12134662B2 (en) Synthetic proteins and therapeutic uses thereof
HK40041518A (en) Recombinant proteins and their therapeutic uses
CN114269792B (zh) 稳定的嵌合合成蛋白及其治疗用途
HK1197890A (en) Recombinant proteins and their therapeutic uses
HK1197890B (en) Recombinant proteins and their therapeutic uses

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20140924